GlassScriptPhysician profile
Michael Yang
NPI 1417338229
$1,010.74
in general payments reported to CMS, 2019-2025
13 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $226 · 2023: $133 · 2024: $543 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $202.55 | 2023-2025 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander, Mentor Memoryshape Breast Implant |
| Integra Lifesciences Corporation | $154.90 | 2022-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Allergan, INC. | $149.90 | 2022 | |
| Abbvie INC. | $137.28 | 2023-2025 | |
| Revance Therapeutics, INC. | $78.11 | 2024 | Daxxify |
| Tela Bio, INC. | $66.71 | 2024-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Axogen | $47.72 | 2022 | |
| Convatec INC. | $42.31 | 2024 | |
| Polynovo North America LLC | $40.43 | 2024 | Novosorb Btm |
| Motiva USA, LLC | $33.00 | 2025 | |
| Musculoskeletal Transplant Foundation INC. | $22.07 | 2024 | |
| Kerecis Limited | $19.71 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Olympus America INC. | $16.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.